R&D

The need for a blueprint emergency plan to avoid a HPAPI crisis

https://pharmaphorum.com/partner-content/the-need-for-a-blueprint-emergency-plan-to-avoid-a-hpapi-crisis/

Bayer begins phase 3 trial testing aflibercept in infant blindness

https://pharmaphorum.com/news/bayer-begins-phase-3-trial-testing-aflibercept-in-infant-blindness/

Working together to embed public involvement in research

https://pharmaphorum.com/views-analysis-patients/abpi-working-together-to-embed-public-involvement-in-research/

Sanofi hands back neurology gene therapy rights to Voyager

https://pharmaphorum.com/news/sanofi-hands-back-neurology-gene-therapy-rights-to-voyager/

Addressing global health challenges: the pharmaphorum podcast

https://pharmaphorum.com/podcast/iavi-global-health-challenges/

Registration opens for SMi’s 3rd Annual Ophthalmic Drugs Conference

https://pharmaphorum.com/partner-content/registration-opens-for-smis-3rd-annual-ophthalmic-drugs-conference/

Ophthalmic Drugs Conference

https://pharmaphorum.com/events/ophthalmic-drugs-conference/

The science of prevention

https://pharmaphorum.com/r-d/views-analysis-r-d/the-science-of-prevention/

VBI craters as investors react to Hep B vaccine data

https://pharmaphorum.com/news/vbi-craters-as-investors-react-to-hep-b-vaccine-data/

Close in 10 seconds

Pharmaphorum.com

Search